Effects of tamoxifen on the breast in the luteal phase of the menstrual cycle

International Journal of Gynecology and Obstetrics

Volumn 62, Issue 1, 1998, Pages 77-82

  Uehara, J ^a,b   Nazario A C P ^a   De Lima, G Rodrigues ^a   Simoes M J ^a   Juliano, Y ^a   Gebrim, L H ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Breast; Mitotic index; Premenopause; Tamoxifen

Indexed keywords

PROGESTERONE; TAMOXIFEN; TECNOTAX; UNCLASSIFIED DRUG;

ARTICLE; BREAST; BREAST BIOPSY; BREAST FIBROADENOMA; CELL NUCLEUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; MITOSIS INDEX; PARENCHYMA; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031856822     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(98)00050-2     Document Type: Article

References (24)

1. Walker KJ, Price-Thomas JM, Candlish W, Nicholson RI. Influence of anti-oestrogen tamoxifen on normal breast tissue. Br J Cancer 1991;64:764-768.
2. Jordan VC. Estrogen receptor antagonists. In: Adashi EY, Rock JA, Rosenwaks Z, editors. Reproductive endocrinology, surgery and technology. Philadelphia: Lippincott-Raven, 1996:527-545.
3. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83:1450-1459.
4. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31.000 recurrences and 24.000 deaths among 75000 women (parts 1 and 2). Lancet 1992; 339(1/15):71-85.
5. Jordan VC. Studies on the estrogen receptor in breast cancer - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 1995;36:267-285.
6. Rochefort H. Mechanism of action of high-affinity anti-estrogen. Am J Clin Oncol 1991;14:S1-4.
7. Wieb VJ, Osborne CK, Fuqua SAW. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 1993;14:173.
8. Ricketts D, Turnbull L, Ryal G. Estrogen and progesterone receptors in the normal breast female. Cancer Res 1991;51:1817.
9. Master JRW, Drife JO, Scarisbrick JJ. Cyclic variation of DNA synthesis in human breast epithelium. J Natl Cancer Inst 1977;58:1263-1265.
10. Meyer JS. Cell proliferation in normal human breast ducts, fibroadenomas and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Hum Pathol 1977;8:67-81.
11. Fanger H, Ree HJ. Cyclic changes of human mammary gland epithelium in relation to the menstrual cycle - an ultrastructural study. Cancer 1974;34:571-585.
12. Masson P. Human tumors: histology, diagnosis and technique. 2nd ed. Paris: Libraire Maloine, 1956:1061-1148.
13. Salvatore CA. About the nature of nuclear hypertrophy of uterine muscle cells during pregnancy. An Bras Ginecol 1948;26:453-462.
14. Siegel S. Non-parametric statistics applied to the behavioral sciences. 2nd ed. Mexico: Trilhas, 1975:346.
15. Nazário ACP, de Lima GR, Simies MJ, Novo NF. Cell kinetics of the human mammary lobule during the proliferative and secretory phase of the menstrual cycle. Bull Assoc Anat 1995;79:23-27.
16. Dupont WD, Page DL, Parl FF, Vnencak-Jone CL, Plummer WD, Rados MS, Schuyler PA. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994;331:10-15.
17. Jordan VC, Fritz NF, Langan-Fahey S. Alteration of endocrine parameters in premenopausal women with breast cancer during low-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 1991;83:1488-1496.
18. Groom GV, Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal premenopausal women. J Endocrinol 1976;70:421-428.
19. Sherman BM, Chapler FK, Crickard K, Wycoff D. Endocrine consequences of continuous anti-estrogen therapy with tamoxifen in premenopausal women. J Clin Invest 1979;64:398-404.
20. Ravdin PM, Fritz NF, Tormey DC, Jordan VC. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 1988;48:1026-1029.
21. Sunderland MC, Osborne CK. Tamoxifen in the premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991;9:1283-1297.
22. Howell A. New endocrine treatments for breast cancer: biological and clinical aspects. Breast 1996;5:170-174.
23. Nicholson RI, Francis AB, Kyme S, Gee JMW. Properties and mode of pure anti-oestrogens in breast cancer in vitro. Breast 1996;5:175-180.
24. Facina G, Rodrigues de Lima G, Simies MJ, Novo NF, Gebrim LH. Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cycle. Int J Gynecol Obst 1997;56:19-24.